drugset
drugset / Trial / NCT07606625

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

NCT07606625 ↗

Phase 4 Recruiting 65 enrolled University of California, Berkeley Viatris Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).

Timeline

Start
2026-03-06
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 0.03 mg Intranasal

Indications

dry eye syndrome